Modalis Therapeutics Corporation
| Code | Sector | Market |
|---|---|---|
| 4883 | Pharmaceuticals | MTH |
| Date of listing approval | 2020/06/26 |
|---|---|
| Expected Date | 2020/08/03 |
| Lead Underwriter | Mizuho |
| Description | Research and development of gene therapy drugs using the core platform technology "Incisive CRISPR technology (CRISPR-GNDM technology)" |
| Listed Shares(total) | 3,105,000 |
|---|---|
| Trading Unit | 100 |
| New Shares | 2,100,000 |
| Existing Shares | 1,005,000（incl. O.A.） |
| Shares Outstanding | PreIPO 25,100,000.00 |
| PostIPO 27,200,000.00 | |
| Paid Up Capital | PreIPO Y1,300,000,000 |
| PostIPO Y2,075,008,000 | |
| Expected Pricing Date | 2020/07/10 |
| Book Building Start | 2020/07/14 |
| Book Building End | 2020/07/20 |
| Fix Date | 2020/07/21 |
| Offering Starts | 2020/07/22 |
| Offering Ends | 2020/07/29 |
| Expect Pricing | Y1,000-Y1,200 |
| Notional PER (based on previous period) |
167.79-201.34 |
| Offering Price | Y1,200 |
| Offering Price PER (based on previous period) |
- |
| Offering Price PBR (based on previous period) |
7.84 |
| Use of Funds Raised |
Financial Data
Units:Y1,000
| Fiscal Year End:2017/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 17,921 |
| Current Profit | - | -141,200 |
| Net Profit | - | -142,150 |
| Net Assets | - | 1,421,735 |
| Fiscal Year End:2018/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | 65,297 | 65,297 |
| Current Profit | -213,390 | -228,981 |
| Net Profit | -217,909 | -229,932 |
| Net Assets | 1,201,779 | 1,191,802 |
| Fiscal Year End:2019/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | 644,500 | 644,500 |
| Current Profit | 146,351 | 128,822 |
| Net Profit | 140,528 | 127,899 |
| Net Assets | 3,842,542 | 3,819,701 |
| Recent Quarter 2020/03 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | 13,000 | - |
| Current Profit | -116,924 | - |
| Net Profit | -118,286 | - |
| Net Assets | 3,724,455 | - |
Per Share Units:Y1
| Fiscal Year End:2017/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -10.29 | -3.89 |
| Fiscal Year End:2018/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | -10.84 | -14.84 |
| Equity | -11.44 | -15.33 |
| Fiscal Year End:2019/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | 5.96 | 153.09 |
| Equity | 5.43 | 152.18 |
| Fiscal Year End:Recent Quarter 2020/03 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | ||
| Net Earning | -4.71 | - |
| Equity | - | - |
Comment
| ■Over allotment(405,000) |
Consolidated Subsidiaries
| Name | Address |
|---|
Underwriters
| Allocation | Underwriter | Tel |
|---|---|---|
| 0% | Nomura | 03-3211-1811 |
| 75% | Mizuho | 03-5208-3210 |
| 11% | SBI SECURITIES Co.,Ltd. | 03-5562-7210 |
| 11% | SMBC Nikko | 03-5644-3111 |
| 1.5% | Ichiyoshi | 03-3555-6210 |
| 1.5% | Ace | 06-6267-2111 |
Data
| Date of incorporation | 2016/01/14 |
|---|---|
| Company address | Tokyo 103-0026 |
| Telephone | 03-6822-4584 |
| President | |
| Homepage | https://www.modalistx.com/jp/ |
| Auditor | Azsa |
| Major Shareholders | |
|---|---|
| Shareholder Name | Ratio |
| 86.62% | |
| 17.86% | |
| 16.07% | |
| 8.39% | |
| 8.39% | |
| 3.75% | |
| 3.57% | |
| 2.86% | |
| 2.68% | |
| 2.68% | |
| 2.59% | |
| Number of Employees | 3 as of 2020/05/31 |
|---|---|
| Birth Date of Representative | 1969/08/09 |